🟢 Structure Therapeutics is trading 4.3% up in pre-market as biotech stocks rally broadly

Structure Therapeutics is trading 4.3% up at $56.47 after biotechnology stocks rallied broadly in pre-market trading.

• The latest official update was August 6, covering second-quarter results and Phase 3 dosing for aleniglipron.
• No newer company-specific announcement was found for August 19–20.
• The broader biotech move, with XBI up 2.27%, appears to be the primary catalyst, supported by positive sector-wide clinical-trial sentiment.